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A. PLANO CIENTÍFICO | SCIENTIFIC PLAN 
1. Introdução e estado da arte | Introduction and state of the art 
Hereditary hemochromatosis (HH) is a primary inherited disorder of iron metabolism with 
progressive iron loading of parenchymal cells of the liver and other organs, which may eventually lead 
to tissue damage and dysfunction, generally by the fourth to fifth decades of life (Porto G et al, 2008; 
Feder JN et al, 1996). Clinical consequences of iron accumulation include cirrhosis of the liver, 
hepatocellular carcinoma, diabetes, heart failure, arthritis and hypogonadism (Cardoso CS et al, 2001). 
Independently of the presenting clinical picture, HH should be suspected in any subject with 
clinical and/or laboratory evidence of severe iron overload, in the absence of other known iron loading 
conditions such as chronic liver disease or hematological disorders. Typically, both transferrin 
saturation (TfSat) and serum ferritin are abnormally high and normally represent the first phenotypic 
manifestation of HH (Porto G et al, 2008). 
With origin in populations of northern European, over 90% of HH patients are homozygote’s to 
C282Y mutation in HFE gene, a non-classical MHC class I gene 5 Mb telomeric to HLA-A at 
chromosome 6 (6p22.1) (Feder JN et al, 1996), while only about 1 in 200 people in the general 
population have this genotype (Jackson HA, 2001).  
Type 1 HH, also called HFE-related HH or classic HH, is the most common form of inherited iron 
overload and one of the most common hereditary metabolic diseases in Caucasians (Cardoso CS et al, 
2001). It is characterized by an autosomal recessive pattern of inheritance and is associated with 
mutation of the HFE gene located on chromosome 6 (Franchini M, 2006).  
In spite of the generally reported high frequency of the C282Y mutation in most European derived 
populations and the finding that most homozygotes for the C282Y mutation of HFE show a common 
biochemical phenotype characterized by high transferrin saturation, the proportion of patients with a 
fully developed phenotype found in clinical practice seems to be very low (Porto G et al, 2008). 
Previous studies showed that patients with high CD4/CD8 ratios display a faster re-entry of iron 
into the serum transferrin pool after intensive phlebotomy treatment, reaching abnormal transferrin 
saturation values more rapidly than patients with normal CD4/CD8 ratios (Reimão R et al, 1991). The 
abnormalities in lymphocyte populations were systematically found in CD8+ T cells and the association 
with total body iron stores could also be reflected in the total lymphocyte count (Porto G et al, 2008). 
A significant inverse relationship of total blood lymphocyte counts and severity of iron overload in HH 
patients with HFE C282Y homozygosity was also described (Barton JC et al, 1995). 
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HH is clinically very heterogeneous, varying from a simple biochemical abnormality to a full-blown 
picture of devastating iron overload disease (Porto G et al, 2008) and recent large population 
screenings are revealing that the clinical penetrance of HH may be lower than previously thought 
(Jackson HA, 2001). Heterogeneity observed in iron accumulation and associated clinical presentation 
may be partially explained by gender, age and environmental factors (Ryan E et al, 1996). There are 
also some genes, like those already associated with iron-storage disease such as transferrin, TfR2, 
ferroportin and ceruplasmin that could be good candidate genes at expression modifiers (Porto G et 
al, 2008). More recently there are growing evidences supporting the notion that other genes at the 
MHC class I region, possibly inherited with the ancestral C282Y containing haplotype are implicated in 
the clinical heterogeneity of HFE-associated HH (Kohgo Y, 2001). 
By extended linkage disequilibrium analysis in the hemochromatosis gene region there was 
founded a highly significant association among the C282Y homozygous and the allele 8 of D6S105 
microsatellite, 2Mb away from HFE gene. Moreover, male patients C282Y homozygous, with the two 
copies of the allele 8 of this microsatellite, were found to have significantly higher hepatic iron indices 
than those heterozygous or nullizygous for this allele. Thus, it was suggested that a gene modifying the 
phenotype of C282Y homozygotes may be localized around the area of D6S105. (Pratiwi R, 1999) 
As mentioned previously, low numbers of CD8+ T cells, both in the peripheral blood and in the 
liver, were shown to be negatively correlated with total body iron stores (Porto G et al, 2008) and 
consequently have a more severe expression of HH (Reimão R et al, 1991). This immunophenotype is 
proposed to be a clinical marker of the severity of iron overload in HH patients (Cruz E et al, 2006). By 
sibpair analysis in hemochromatosis families it was shown that CD8+ T-lymphocyte numbers are 
genetically regulated by genes in the MHC region (Cruz E et al, 2004). More recently it has been shown 
that a genetic trait associated with the transmission of CD8+ T lymphocyte numbers is also 
demonstrated in the normal population and it is localized at the MHC class I region close to the 
D6S105 microsatellite marker (Vieira J et al, 2007). 
The referred evidences led to the formulation of the hypothesis that a putative gene controlling 
CD8+ T cells numbers, localized on the MHC region, could be the same gene contributing to the clinical 
heterogeneity observed in HH (Porto G et al, 2008; Cruz E et al, 2008). 
Previous studies performed in our group, using a small group of HH patients, have suggested that 
the that a highly conserved 500 Kb ancestral haplotype defined by the SNP markers PGBD1-A, ZNF193-
A, ZNF165-T (AAT haplotype) marks the inheritance of “low” CD8+ T-lymphocyte numbers and predicts 
the development of a severe clinical expression of HH (in terms of iron overload and clinical 
manifestations) (Cruz E et al, 2008). In order confirm these studies, haplotype analysis will be done in 
the region 500Kb defined by the SNP markers PGBD1, ZNF193 and ZNF165, in a larger group of 
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previously characterized C282Y homozygous Portuguese HH patients. Once identified and described 
the different conserved haplotypes in that region, the results with be correlated with the phenotypic 
and clinical variables. 
2. Problemas | Pitfalls 
HH is clinically very heterogeneous, varying from a simple biochemical abnormality to a full-blown 
picture of devastating iron overload disease. Nevertheless, there is no a genetic marker that make us 
able to predict the clinical severity. 
3. Hipótese de trabalho | Working hypothesis 
Our general working hypothesis is that a putative gene controlling CD8+ T cells numbers, localized 
on the MHC region, is the same gene contributing to the clinical heterogeneity observed in HH. 
Specifically, we hypothesize that in the region of 500 kb defined by the SNP markers PGBD1, ZNF193, 
ZNF196, there may be a gene that affects inheritance of CD8+ T-lymphocyte numbers and predicts the 
development of a severe clinical expression of HH (in terms of iron overload and clinical 
manifestations). 
4. Objectivos | Aims 
General: To find new markers that could be used as more reliable prognostic variables in HH. 
Specific: To confirm previous studies suggesting that in the region of 500 kb defined by the SNP 
markers PGBD1, ZNF193, ZNF196 there is a genetic marker predicting both the inheritance of CD8+ T-
cell numbers and the severity of phenotypic expression in HH. 
5. Implicações | Implications 
The results of this study may have important implications not only for approaching the question of 
the penetrance of the hemochromatosis gene in Portuguese population but also to further narrow the 
region of interest to find a candidate gene involved in the setting of CD8+ T-lymphocyte numbers in 
humans. 
 
6. Enquadramento, motivações e condições de suporte | motivations and support 
conditions 
A Orientadora integra o IBMC/UP uma Instituição de Investigação da Universidade do Porto 
reconhecida pela FCT. 
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Têm grande experiência no estudo da HH: Desenvolvimento de tese de doutoramento sobre HH; 
Realiza a consulta de HH do serviço de Hematologia Clínica do HSA/CHP e consulta de diagnóstico 
genético de HH do CGPP; 
Têm desenvolvido diversos projectos de investigação: 
Porto G, Cruz E, Miranda HP, Porto B, Vasconcelos JC, Lacerda R, Roetto A, Daraio F and Bacelar C. 
Growth hormone (GH)-induced reconstitution of CD8+ CD28+ T lymphocytes in a rare case of 
severe lymphopenia associated with Juvenile Haemochromatosis and Turner's syndrome. Clinical 
Endocrinology Aug 2004, 61: 437-440. 
Porto G, Cardoso CS, Gordeuk V, Cruz E, Fraga J, Areias J, Oliveira JC, Bravo F, Gangaidzo IT, MacPhail 
AP, Gomo ZAR, Moyo VM, Melo G, Silva C, Justiça B and de Sousa M. Clinical and genetic 
heterogeneity in hereditary haemochromatosis: association between lymphocyte counts and 
expression of iron overload. European Journal of Haematology Apr 2002, 67:  110-118. 
Porto G, Cardoso CS, Gordeu, Cruz E, Fraga J, Areias J, Oliveira JC, Bravo F, Gangaidzo IT, MacPhail AP, 
Gomo ZA, Moyo VM, Melo G, Silva C, Justica B and de Sousa M. Clinical and genetic heterogeneity 
in hereditary hemochromatosis: association between lymphocyte counts and expression of iron 
overload. Eur J Haematol 2001, 67:110-8. 
Porto G, Reimão R, Gonçalves C, Vicente C, Justiça B and de Sousa M. Haemochromatosis as a window 
into the study of the immunological system: A novel correlation between CD8+ lymphocytes and 
iron overload. European Journal of Haematology 1994, 52: 283-290. 
Tem redigido vários artigos de revisão: 
Porto G and de Sousa M. Iron overload and immunity. World J Gastroenterol, Sep 2007, 21:4707-15. 
Porto G, Cardoso CS, Macedo F, and Cruz E. Hereditary Hemochromatosis type I: Genetic, clinical and 
immunological aspects. Iron Metabolism and Disease. 2008: 435-460. 
Tem coordenado inúmeros projectos de investigação: 
 Correia AP, Pinto JP, Dias V, Mascarenhas C, Almeida S and Porto G. CAT53 and HFE alleles in 
Alzheimer's disease: a putative protective role of the C282Y HFE mutation. Neurosci Lett. Jul 2009, 
3: 129-32. 
 Porto B, Vieira R and Porto G. Increased capacity of lymphocytes from hereditary 
hemochromatosis patients homozygous for the C282Y HFE mutation to respond to the genotoxic 
effect of diepoxybutane. Mutat Res. Feb 2009, 19: 37-42. 
 Cruz E, Whittington C, Krikler SH, Mascarenhas C, Lacerda R, Vieira J and Porto G. A new 500 kb 
haplotype associated with high CD8+ T-lymphocyte numbers predicts a less severe expression of 
hereditary hemochromatosis. BMC Med Genet. Nov 2008, 6: 97. 
 Cruz E, Melo G, Lacerda R, Almeida S and Porto G. The CD8+ T-lymphocyte profile as a modifier of 
iron overload in HFE hemochromatosis: An update of clinical and immunological data from 70 
C282Y homozygous subjects. Blood Cells, Molecules and Diseases, July-August 2006, 37: 33-39. 
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 Cruz E, Vieira J, Almeida S, Lacerda R, Gartner A, Cardoso CS, Alves H and Porto G. A study of 82 
extended HLA haplotypes in HFE-C282Y homozygous hemochromatosis subjects: relationship to 
the genetic control of CD8+ T-lymphocyte numbers and severity of iron overload. BMC Med 
Genet. Mar 2006, 1: 16. 
É coordenada ainda de diversos projectos de pós-graduação (dissertações de mestrado e teses de 
doutoramento). 
Concomitantemente encontra-se a organizar o encontro anual da International BioIron Society: 
“IBIS 2009 Annual Meeting”. 
Motivações do aluno: 
 Vontade em melhorar os conhecimentos sobre a patologia em questão (HH) quer da sua 
componente clínica quer da sua componente genética. 
 Obter experiência em investigação clínica como premissa para aumento do interesse científico e 
desenvolvimento do espírito inquisitivo. 
 Aperfeiçoamento e aprendizagem de técnicas e procedimentos laboratoriais. 
 Reconhecimento pelos pares. 
7. Desenho do estudo e metodologia | Study design and working 
7.1. População em estudo | Study population 
The population analyzed in this study will be composed by all the individuals homozygous for the 
C282Y mutation of the HFE gene (approximately 240 individuals) identified between 1997 and 2009 in 
the Centro de Genética Preventiva e Predictiva (CGPP), Porto. These subjects are Caucasians from the 
north and centre of Portugal and included subjects detected in the context of suggestive clinical 
picture of haemochromatosis, generally with related clinical manifestations, or detected accidentally 
after a routine test and generally asymptomatic or even family members detected in the context of 
systematic family screening programs. 
7.2. Caracterização clínica | Clinical characterization 
Clinical evaluation of the group of C282Y homozygous Portuguese patients was previously described in 
detail elsewhere (Porto G et al, 2001; Cruz E et al, 2006). They include both asymptomatic and 
symptomatic HH patients presenting with one or more of the following manifestations: liver cirrhosis 
/fibrosis, diabetes, arthropathy, hypopituitarism, skin pigmentation or cardiac abnormalities, and 
removed an average of iron stores by intensive phlebotomies. The clinical parameters used in the 
analysis will include: biochemical parameters of iron metabolism (TfSat and serum ferritin) determined 
at diagnosis by standard techniques as described (Porto G et al, 2001), total body iron stores (TBIS) 
determined by quantitative phlebotomies (Haskins D et al, 1952) and the presence of clinical 
manifestations related to HH. Whenever necessary, missing clinical data will be obtained by contacting 
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the physicians that accompanies those patients and sending them a formulary for clinical data 
registering (Attachment 1).  
7.3. Caracterização imunológica | Immunological characterization 
The immunological characterization of patients included the number of peripheral blood total 
lymphocytes. For the purpose of phenotypic characterization of patients, total lymphocyte numbers 
were considered “low” when they were ≤ 2,12x106/ml and were considered “high” when > 
2,12x106/ml, as defined in previous studies of lymphocyte populations in hemochromatosis (Cruz E et 
al, 2006a; Cruz E et al, 2004; Cruz E et al, 2006b). These cut-off values were based on the median 
values of the parameters previously established on a control population from the north of Portugal 
(Cruz E et al, 2006a). 
7.4. Caracterização genética | Genetic characterization 
All subjects had been previously genotyped for HFE mutations (H63D and C282Y) and they are all 
homozygous for the C282Y mutation. Some HH patients were also previously genotyped for D6S105, 
PBGD1 and ZNF193. Genetic data have been partially published (Cruz E et al, 2004; Cruz E et al, 2008). 
7.5. Definição do haplótipo | Haplotype definition 
For the purpose of this study, extended haplotypes will be inferred using the program PHASE 
(http://www.stat.washington.edu/stephens/software.html), as described previously (Vieira J et al, 
2007). Extended haplotypes will be defined with the information of the genotype of following 
markers:  PGBD1 and ZNF193. The phase of length polymorphisms at microsatellite D6S105 was 
known from family studies, and this information will be used when running PHASE.  
7.6. Desenho experimental | Experimental design 
For the purpose of this study, some single nucleotide polymorphisms (SNPs) localized in the region 
around the microsatellite in the 6p21.3 region, and in the HLA-A region will be genotyped in all 
patients. The SNPs are localized in the following genes:  piggyBac transposable element derived 1 gene 
(PGBD1) e zinc finger protein (ZNF) 193. The other SNPs, and respective characterization, used in this 
study are from some studies that still ongoing. 
SNP genotyping will be performed by gene sequencing. Briefly, genomic DNA (gDNA) will be extracted 
from peripheral blood or stored. gDNA and amplicons containing the selected loci will be PCR-
amplified using specific primers. Amplicons will be then electrophoresed and extracted from the gel 
whit the QIAquick Gel Extraction Kit (Quiagen). Sequencing reaction will be prepared with the Big Dye 
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Terminator v1.1 Cycle Sequencing kit (Applied Biosystems) and loaded in an ABI prism 310 Genetic 
Analyzer Sequencer (Applied Biosystems). 
7.7. Análise estatística | Statistic analysis 
Association studies between the total lymphocytes numbers and the genetic markers will be 
performed. Since each subject carries two haplotypes, the analyses will be performed considering the 
combination of the inherited conserved haplotypes. Finally, the combination of conserved haplotypes 
will be used to analyze its impact on the clinical expression of the disease, both in terms of the amount 
of iron mobilized by phlebotomies (TBIS) and the clinical manifestations. 
For the statistical analyses that include total lymphocytes numbers, patients with clinical conditions 
known to influence those numbers (such as autoimmune or viral diseases) will be excluded. 
The Chi-square test will be used to test the fitness of data to the normal distribution. Independence 
between categorical data was tested using Chi-square test. The Yates correction will be used when 
small samples (<5) were tested. 
All statistical tests will be performed at 0.05 level of significance and all p values are two-sided.  
Data will be analyzed by SPSS, version 17. 
8. Tarefas | Tasks 
8.1. Fase pré-projecto |Pre Project 
 Literature review and project elaboration  
o Sandra Morais 
o January to March, 2009 
 Identification of participants 
o Prof. Doutora Graça Porto 
o April to August, 2009 
8.2. Fase projecto | Project 
 Clinical data registering  
o Sandra Morais, under supervision of Prof. Doutora Graça Porto 
o September to December, 2009. 
 Execution of laboratory exams 
o Sandra Morais, helped by Mónica Costa and Susana Almeida 
o September 2009 to March 2010 
 Statistical analysis 
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o Jorge Vieira and Sandra Morais, under supervision of Prof. Doutora Graça Porto 
o January to March, 2010. 
 Data interpretation and discussion / conclusions  
o All 
o April to May, 2010 
9. Indicadores de produção científica | Scientific deliverables 
The research proposal will be presented in the Clinical Hematology Service and at the “Jornadas de 
Iniciação à Investigação Clínica” (June 2009). 
The results will be presented as oral communication or poster at the “Jornadas de Iniciação à 
Investigação Clínica” (June 2010). 
Efforts will also be made in order to publish a paper in a peer-review journal. 
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B. QUESTÕES ÉTICAS | ETHICAL CONSIDERATIONS 
This project is part of a HH study that was already approved by the ethical committee of Hospital.  
Patients included in this study have previously signed the Informed Consent terms in use in the CGPP 
(Attachments 2 and 3).  
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C. PLANO FINANCEIRO | BUDGET AND FUNDING 
1. Orçamento | Budget 
Não haverá episódios (consultas, internamentos, etc.), exames, análises ou outros procedimentos no CHP. 
Não haverá custos para o CHP. 
 Custo estimado 1 
 90 participantes 2 
(2 primers – 180 amostras) 
180 participantes 3 
(2 primers – 360 amostras) 
Despesas relacionadas com os estudos 
genéticos (primers, despesas de sequênciação, 
outros reagentes de laboratório, material de 
laboratório, etc.) 
3234,6 Euros 6469,2 Euros 
Transporte de amostras, material 
administrativo e outros consumíveis 
100,00 Euros 100,00 Euros 
Sub-Total 3334,60 Euros 6569,20 Euros 
Poster  50,00 Euros 50,00 Euros 
Inscrição aluno em Congresso da Especialidade 200,00 Euros 200,00 Euros 
Organização das Jornadas de Iniciação à 
Investigação Clínica 
50,00 Euros 50,00 Euros 
Sub-Total 300,00 Euros 300,00 Euros 
 
TOTAL 3634,60 EUROS 6869,20 EUROS 
2. Financiamento | Funding 
This project will be partially financed by Roche Farmacêutica (Bolsa de Iniciação à Investigação Clínica 
– Programa Roche/ICBAS/HSA 2008/2010). 
 
                                                          
1
 Custo aproximado de cada primer: 7,02 euros; Despesas relacionadas com a sequênciação: 10,95 euros. 
2
 Financiamento solicitado – Bolsa de Iniciação à Investigação Clínica. 
3
 Se forem encontradas outras fontes de financiamento para além da Bolsa de Iniciação à Investigação Clínica, serão 
estudados 180 indivíduos. 
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ABREVIATURAS e ACRÓNIMOS | ABBREVIATIONS 
CGPP, Centro de Genética Preventiva e Predictiva 
CHP, Centro Hospitalar do Porto 
DIIC, Disciplina de Iniciação à Investigação Clínica do Curso de Mestrado Integrado em Medicina do 
ICBAS 
ESTSP, Escola Superior de Tecnologia da Saúde do Porto 
FCUP, Faculdade de Ciências da Universidade do Porto 
FFUP, Faculdade de Farmácia de Universidade do Porto 
FMUP, Faculdade de Medicina da Universidade do Porto  
HH, Hemocromatose hereditária 
HSA, Hospitalar de Santo António 
IBMC/UP, Instituto de Biologia Molecular e Celular da Universidade do Porto 
ICBAS/UP, Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto 
JIIC, Jornadas de Iniciação à Investigação Clínica 
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ANEXOS | ATTACHMENTS  
Anexo 1: Formulário de registo de dados clínicos | Clinical data registering formulary 
Anexo 2: Requisição de testes genéticos | Formulary to request genetic studies (CGPP) 
Anexos 3 e 4: Termos de consentimento informado | Informed consents (CGPP) 
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PEDIDOS DE AUTORIZAÇÃO INSTITUCIONAL 
HSA/CHP 
Carta ao Presidente do Conselho de Administração 
 
Exmo. Senhor Presidente do Conselho de Administração do Centro Hospitalar do Porto 
Dr. Sollari Allegro 
 
SANDRA ISABEL ALVES MORAIS, na qualidade de Aluna da Disciplina de Iniciação à Investigação 
Clínica do Curso de Mestrado Integrado em Medicina do ICBAS/HSA, vem por este meio, solicitar a 
Vossa Exa. autorização para realizar no Centro Hospitalar do Porto o Estudo de Investigação / Trabalho 
Académico acima mencionado, de acordo com o programa de trabalhos e os meios apresentados. 
 
Data     Assinatura 
 
Carta à Presidente da Comissão de Ética 
 
Exma. Senhora Presidente da Comissão de Ética para a Saúde do Centro Hospitalar do Porto 
Dra. Luísa Bernardo 
 
SANDRA ISABEL ALVES MORAIS, na qualidade de Aluno da Disciplina de Iniciação à Investigação 
Clínica do Curso de Mestrado Integrado em Medicina do ICBAS/HSA, vem por este meio, solicitar a 
Vossa Exa. autorização para realizar no Centro Hospitalar do Porto o Estudo de Investigação / Trabalho 
Académico acima mencionado, de acordo com o programa de trabalhos e os meios apresentados. 
 
Data     Assinatura 
 
Carta ao Director do Departamento de Ensino, Formação e Investigação 
 
Exma. Senhora Directora do Departamento de Ensino, Formação e Investigação do Centro Hospitalar 
do Porto 
Prof. Doutora Margarida Lima 
 
 
SANDRA ISABEL ALVES MORAIS, na qualidade de Aluna da da Disciplina de Iniciação à 
Investigação Clínica do Curso de Mestrado Integrado em Medicina do ICBAS/HSA, vem por este meio, 
solicitar a Vossa Exa. autorização para realizar no Centro Hospitalar do Porto o Estudo de Investigação 
/ Trabalho Académico acima mencionado, de acordo com o programa de trabalhos e os meios 
apresentados. 
 
Data     Assinatura 
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PEDIDO DE FINANCIAMENTO 
Bolsa de iniciação à investigação clínica 
Carta ao Presidente do Conselho Directivo 
 
Exmo. Senhor Presidente do Conselho de Directivo do Instituto de Ciências Biomédicas Abel Salazar da 
Universidade do Porto 
 
Prof. Doutor António Sousa Pereira 
 
SANDRA ISABEL ALVES MORAIS, na qualidade de Aluno da Disciplina de Iniciação à Investigação 
Clínica do Curso de Mestrado Integrado em Medicina do ICBAS/HSA, vem por este meio, solicitar a 
Vossa Exa. a atribuição de 6869,20€ (seis mil oitocentos e sessenta e nove euros e vinte cêntimos) da 
Bolsa de Iniciação à Investigação Clínica da Roche Farmacêutica, SA, para financiamento do Estudo de 
Investigação / Trabalho Académico acima mencionado, de acordo com orçamento apresentado. 
 
Data     Assinatura
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TERMOS DE RESPONSABILIDADE 
Investigador Responsável 
 
Termo de Responsabilidade do Investigador Principal e Responsável no CHP 
 
Eu, abaixo assinado, MARIA DA GRAÇA BESSA GONÇALVES PORTO, Médica, 
Especialista de Imunohemoterapia do Serviço de Hematologia Clínica do HSA/CHP, na 
qualidade de Investigador Principal e Responsável no HSA/CHP, declaro assumir a liderança 
científica do Estudo de Investigação / Trabalho Académico acima mencionado, de acordo com 
o programa de trabalhos e os meios apresentados e com as normas internas da Instituição. 
  
Data     Assinatura 
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DECLARAÇÕES DE ALUNOS E ORIENTADORES / SUPERVISORES 
Aluno 
Declaração do Aluno 
Eu, abaixo assinado, SANDRA ISABEL ALVES MORAIS, na qualidade de Aluna da 
Disciplina de Iniciação à Investigação Clínica do Curso de Mestrado Integrado em Medicina do 
ICBAS / CHP, declaro que durante a realização do Trabalho Académico acima mencionado, 
respeitarei as normas éticas e deontológicas, que a identificação dos doentes não será 
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Durante o desenvolvimento do projecto este teve de ser alterado devido 
a resultados obtidos entretanto que nos fizeram enveredar por uma nova linha 
de pensamento. 
Esses resultados confirmavam a elevada frequência do haplótipo AAT 
relativamente ao haplótipo GGG na população portuguesa de doentes com 
Hemocromatose Hereditária (HH) bem como confirmavam os resultados 
prévios obtidos por Cruz e colaboradores (Cruz E, Whittington C, Krikler SH, 
Mascarenhas C, Lacerda R, Vieira J, Porto G: A new 500 kb haplotype 
associated with high CD8+ T-lymphocyte numbers predicts a less severe 
expression of hereditary hemochromatosis. BMC Med Genet 2008, 9:97.) 
relativamente à associação observada entre estes haplótipos restritos, o 
número de linfócitos T CD8+ e a expressão clínica da doença, sugerindo que 
poderiam constituir marcadores de prognóstico importantes. Apesar dessa forte 
associação, os haplótipos SNP restritos AAT ou GGG não explicavam, 
contudo, toda a variabilidade existente no número de linfócitos T CD8+. De 
facto, uma proporção importante de doentes homozigóticos para o AAT 
(33.3%) tem número de linfócitos T CD8+ elevados, o que demonstra a 
necessidade de estudar outros marcadores genéticos na região na tentativa de 
melhor perceber a contribuição da região MHC na determinação do número de 
linfócitos T CD8+. Tendo em conta o grande desequilíbrio de ligação nessa 
região (Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, 
Dormishian F, Domingo R, Jr., Ellis MC, Fullan A et al: A novel MHC class I-like 
gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 
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13(4):399-408.), uma análise combinada com marcadores genéticos mais 
distantes, como os alelos e haplótipos HLA, é necessária. 
Assim à luz dos novos resultados tornou-se pertinente alterar o titulo do 
trabalho de “Characterization of haplotypes AAT and GGG in a population 
of individuals homozygous for the C282Y mutation in HFE gene: 
contribution to the study of penetrance of hereditary hemochromatosis.”, 
para um titulo mais abrangente e que melhor descreve todos os resultados 
obtidos: “A study of 147 extended haplotypes carrying the C282Y HFE 
mutation: a novel approach to explain the involvement of the MHC-class I 
region in the setting of CD8+ T-lymphocyte numbers in humans.” 
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Abstract 
Background: The numbers of peripheral blood CD8+ T lymphocytes are 
known to be genetically determined in the context of genes at the MHC-class I 
region. The present study analyses, for the first time, the inheritance of CD8+T 
lymphocytes in the context of extended haplotypes defined between HFE and 
HLA-B by segregation analysis in families of Hereditary Hemochromatosis (HH) 
patients. With this novel approach we aimed to clarify the relative impact of the 
HLA specificities or the whole haplotype on the genetic transmission of CD8+T 
lymphocytes in humans. 
Subjects and Methods: A total of 71 unrelated C282Y homozygous HH 
patients and 61 of their family members were studied for extended haplotype 
analysis, performed by segregation analysis for the SNP markers on PGBD1, 
ZNF193 and ZNF165 (defining the restricted SNP haplotypes AAT and GGG) 
and for the HLA-A and -B loci, all correlated with the numbers of CD8+T 
lymphocytes. In addition, 123 DNA samples from an independent population of 
C282Y homozygous subjects were tested to confirm the frequencies of the SNP 
markers in the Portuguese HH population.  
Results: The relative frequencies of the AAT and GGG haplotypes in the 
population of C282Y homozygous HH patients was 94.3% and 4.9% 
respectively. We confirmed the strong association of the most common HLA-
A*03, -B*07 and the A3B7-AAT ancestral haplotype with the inheritance of low 
CD8+T lymphocytes. The HLA-A*03 was the only HLA allele increased in 
frequency in patients with high lymphocytes. The definition of extended 
haplotypes allowed us to construct a model with all patients’ chromosomes 
classified as carrying a “low” or “high CD8+ trait” and to compare the distribution 
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of HLA alleles and haplotypes between the two groups. The results clearly 
showed a greater allelic and haplotypic variability in the “high” vs the “low CD8+ 
trait” group supporting the hypothesis of a different recombination history. 
Conclusions: The study of extended haplotypes carrying the C282Y 
HFE mutation offers a new model to explain the contribution of the MHC region 
to the setting of CD8+T lymphocyte numbers. The results support the 
hypothesis of a putative still unidentified trait localized centromeric to HLA-A. 
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Background 
Hereditary hemochromatosis (HH) is a primary inherited disorder of iron 
metabolism with progressive iron loading of parenchymal cells of the liver and 
other organs, which may eventually lead to tissue damage and dysfunction, 
generally by the fourth to fifth decades of life. Clinical consequences of iron 
accumulation include cirrhosis of the liver, hepatocellular carcinoma, diabetes, 
heart failure, arthritis and hypogonadism (reviewed in [1]). Independently of the 
presenting clinical picture, HH should be suspected in any subject with clinical 
and/or laboratory evidence of severe iron overload, in the absence of other 
known iron loading conditions such as chronic liver disease or hematological 
disorders. Typically, both transferrin saturation (TfSat) and serum ferritin are 
abnormally high and normally represent the first phenotypic manifestation of HH 
[1]. 
HH represents the most common form of inherited iron overload and one 
of the most common hereditary metabolic diseases in Caucasians [2]. It is 
characterized by an autosomal recessive pattern of inheritance associated with 
the C282Y mutation of the HFE gene, a non-classical MHC class I gene 5 Mb 
telomeric to HLA-A at chromosome 6 (6p21.3) [3-4]. 
With origin in populations of northern European, over 90% of HH patients 
are homozygotes to the C282Y mutation in the HFE gene. About 1 in 200 
people in the general population have this genotype [5]. In Portugal, the 
distribution of the C282Y mutation varies from north to south of the country with 
allele frequency reaching the 6% in the north [2]. 
In spite of the generally reported high frequency of the C282Y mutation in 
most European derived populations and the finding that most homozygotes for 
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the C282Y mutation of HFE show a common biochemical phenotype 
characterized by high transferrin saturation, the proportion of patients with a 
fully developed phenotype found in clinical practice seems to be very low [1]. 
HH is clinically very heterogeneous, varying from a simple biochemical 
abnormality to a full-blown picture of devastating iron overload disease [1] and 
recent large population screenings are revealing that the clinical penetrance of 
HH may be lower than previously thought [5]. Heterogeneity observed in iron 
accumulation and associated clinical presentation may be partially explained by 
gender, age and environmental factors [6]. There are also some genes, like 
those already associated with iron-storage disease such as transferrin, TfR2, 
ferroportin and ceruplasmin that could be good candidate genes at expression 
modifiers [1]. More recently there are growing evidences supporting the notion 
that other genes at the MHC class I region, possibly inherited with the ancestral 
C282Y containing haplotype are implicated in the clinical heterogeneity of HFE-
associated HH [7]. 
Previous studies showed that patients with high CD4/CD8 ratios display 
a faster re-entry of iron into the serum transferrin pool after intensive 
phlebotomy treatment, reaching abnormal transferrin saturation values more 
rapidly than patients with normal CD4/CD8 ratios [8]. The abnormalities in 
lymphocyte populations were systematically found in CD8+ T cells and the 
association with total body iron stores (TBIS) could also be reflected in the total 
lymphocyte count [1]. A significant inverse relationship of total blood lymphocyte 
counts and severity of iron overload in HH patients with HFE C282Y 
homozygosity was also described [9]. 
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By extended linkage disequilibrium analysis in the hemochromatosis 
gene region it was found a highly significant association of the allele 8 of 
D6S105 microsatellite, 2Mb away from HFE gene, and the C282Y homozygous 
patients. Moreover, male patients, with the two copies of the allele 8 of this 
microsatellite, were found to have significantly higher hepatic iron indices than 
those heterozygous or nullizygous for this allele. Thus, it was suggested that a 
gene modifying the phenotype of C282Y homozygotes may be localized around 
the area of D6S105 [10]. 
As mentioned previously, low numbers of CD8+ T cells, both in the 
peripheral blood and in the liver, were shown to be negatively correlated with 
total body iron stores [1] and consequently have a more severe expression of 
HH [8]. This immunophenotype is proposed to be a clinical marker of the 
severity of iron overload in HH patients [11]. By sibpair analysis in 
hemochromatosis families it was shown that CD8+ T lymphocyte numbers are 
genetically regulated by genes in the MHC region, and for the first time was 
demonstrated in humans that CD8+ T lymphocytes are genetically determined 
in association with HLA [12]. More recently it has been shown that a genetic co-
dominant trait associated with the transmission of CD8+ T lymphocyte numbers 
is also demonstrated in the normal population and it is localized at the MHC 
class I region close to the D6S105 microsatellite marker [13]. 
Previous studies performed in a group of 56 HH patients suggested that 
a highly conserved 500 Kb ancestral haplotype (around the microsatellite 
D6S105) defined by the SNP markers PGBD1-A, ZNF193-A, ZNF165-T (AAT 
haplotype) marks the inheritance of “low” CD8+ T lymphocyte numbers and 
predicts the development of a severe clinical expression of HH (in terms of iron 
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overload and clinical manifestations) [14]. The referred evidences led to the 
formulation of the hypothesis that a putative gene controlling CD8+ T cells 
numbers, localized on the MHC region, could be the same gene contributing to 
the clinical heterogeneity observed in HH [1, 14]. An important pending question 
is if the genetic modifier determining CD8+ T lymphocyte numbers is “the HLA 
itself” or if there another “still unidentified gene” transmitted in linkage with HLA 
and HFE, as suggested by the associations with AAT/GGG [14] and therefore a 
relevant genetic modifier. 
So far, all association studies relating CD8+ T lymphocyte numbers with 
the MHC-class I region [12-15] were performed using information on particular 
alleles or small haplotypes only. In the present study we analyse, for the first 
time, the inheritance of CD8+ T lymphocytes in the context of extended 
haplotypes defined between HFE and HLA-B by segregation analysis in families 
of HH patients. With this novel approach we aimed to clarify the relative impact 
of the HLA specificities or the whole haplotype on the genetic transmission of 
CD8+ T lymphocytes. 
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Subjects and Methods 
SAH Study Population 
Patients 
A total of 71 unrelated Hereditary Hemochromatosis (HH) patients, 
regularly followed-up at the Hemochromatosis Outpatient Clinic of Santo 
António Hospital (SAH) in Porto, were analyzed for the present study. This 
population consisted of 49 males (mean age 48 ± 14 years, range 6–75) and 22 
females (mean age 45 ± 14 years, range 18–67). Clinical and genetic 
information from these subjects was available from their hospital clinical 
records. All subjects had been previously genotyped for HFE mutations and 
they were all selected by the sole criterion of being homozygous for the HFE 
C282Y mutation. Most HH patients (n=56) had been previously genotyped for 
HLA (on the loci HLA-A and HLA-B) and other SNP markers at the MHC-class I 
region (on the PGBD1, ZNF193 and ZNF165 genes) in the context of other 
previously published studies [12, 14-15]. The remaining 15 were selected for 
genotyping for the SNP marker on PGBD1 (assumed to be inherited in linkage 
disequilibrium with the other haplotypic SNP markers on ZNF193 and ZNF165) 
and for the HLA loci –A and –B for the purpose of the present study. Only 3 
patients could not be SNP genotyped because there were not DNA samples 
available. The study was approved by the ethical committee of Santo António 
Hospital including an informed consent obtained from subjects according to the 
Helsinki declaration. 
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Family members 
In order to define the extended haplotypes in the above described 
population of unrelated subjects, as well as to test the relationship between the 
extended haplotypes and the CD8+ T cell profile, data from patients’ first 
degree relatives were also analyzed. For this purpose, we reviewed the genetic 
and phenotypic data from a total of 61 selected subjects belonging to 32 
different families whose information was available on the hospital clinical 
database since it had been previously performed in the course of a family 
screening program for hemochromatosis. The selection of subjects was done in 
order to get informative cases for the purpose of: 1) genotype/phenotype 
correlations (on C282Y homozygous subjects only) and 2) for haplotype 
definition by segregation analysis (non-identical siblings or offsprings). The 
family population included 48 C282Y homozygous (28 males, mean age 35 ± 
17 years, range 4–63, and 20 females, mean age 46 ± 14 years, range 19–65) 
and 13, non-C282Y homozygous, genetically informative relatives (10 males 
and 3 females). Information on HLA and SNP genotyping was available in all 
except 23 subjects who were therefore genotyped for the purpose of the 
present study using frozen DNA that had been previously stored with their 
informed consent for its use for research purposes. In 16 families it was not 
possible to obtain familiar information either because there were not informative 
cases available or because there was not stored DNA available. In these cases, 
the haplotype inference was done using the PHASE program (see below). 
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CGPP HH population 
In order to confirm the expected frequency of the restricted SNP 
haplotypes AAT and GGG (as defined by Cruz and co-workers in 2008 [14]) in a 
larger Portuguese HH population, an additional independent sample of 
unrelated C282Y homozygous HH patients was genotyped for the haplotypic 
SNP marker on PGBD1, assumed to be inherited in linkage disequilibrium with 
the other haplotypic markers on ZNF193 and ZNF165 (see Table 1). This 
population consisted of a total of 123 patients (97 males, mean age 45 ± 14 
years, range 17–74; 26 females, mean age 49 ± 14 years, range 25–74) that 
had been referred for the genetic diagnosis of HH at the Predictive and 
Preventive Genetic Center (CGPP) in Porto between 1997 and 2009, and they 
were selected by the sole criterion of being homozygous for the C282Y 
mutation. Seventeen of these (8 males and 9 females) were found to be 
identical siblings of other patients and therefore their information was not taken 
into account to estimate the frequency of the restricted SNP haplotypes. Frozen 
DNA samples were available from all subjects, and they all had been previously 
stored with the patients’ informed consent to use for research purposes.  
 
Control population 
For the purpose of comparing the HLA allele and haplotype frequencies 
between HH patients and a representative normal Portuguese control 
population from the same geographical region, the published data [16], from a 
total of 7937 individuals (corresponding to 15874 HLA-A and -B alleles and 
15874 HLA haplotypes) from the region of Porto, Portugal was used. These 
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data are available online at: “New Allele Frequency Database: 
http://www.allelefrequencies.net.  
 
Genetic characterization of subjects 
HFE genotyping 
 All subjects included in the study had been previously genotyped for the 
HFE mutations C282Y and H63D at the Predictive and Preventive Genetic 
Center, Porto (CGPP), between 1997 and 2009, by using the 
Haemochromatosis Strip Assay (Vienna Laboratory, Vienna, Austria) based on 
PCR amplification of the gene with subsequent detection of the mutations by 
allele-specific hybridization with oligonucleotide probes immobilized in test 
strips. Genotype information was available in their clinical records. All HH 
patients and their identical siblings were homozygous for the C282Y mutation. 
Family subjects selected as informative cases for haplotype definition were 
heterozygous for the C282Y mutation on HFE. 
 
SNP genotyping 
For the purpose of defining the restricted SNP haplotypes designated as 
“AAT” and “GGG” by Cruz and co-workers in 2008 [14] in the populations of HH 
patients from CGPP or from HSA who had not been previously characterized for 
these haplotypes (see populations descriptions above), 195 DNA samples were 
genotyped for the SNP rs1997660 in the piggyBac transposable element 
derived 1 gene (PGBD1) localized in the 6p21.3 region, assumed to be 
inherited in linkage with the other two SNPs that define the restricted haplotype, 
i.e. the SNP  rs7206 in the zinc finger protein 193 (ZNF193) and the SNP 
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rs203878 in the zinc finger protein 165 (ZNF165). Since the GGG haplotype in 
HH patients is known to be much less conserved than the AAT haplotype [14], 
its presence was always confirmed by further testing all samples carrying the G-
allele on PGBD1 for the other 2 SNPs on  ZNF193 and ZNF165.  
SNP genotyping of PGBD1 and ZNF193 were performed by Allele-
Specific PCR (AS-PCR). AS-PCR consists of two PCR reactions each one 
using specific primers differing at 3’ end matching one or the other nucleotide 
variant of the SNP. Positive controls (homozygous for the allele variant) and 
negative controls (without the allele) were used in all PCR reactions. The PCR 
products were electrophoresed and sample amplifications were compared with 
the specific controls. The two SNPs (rs1997660 on PGBD1 and rs7206 on 
ZNF193) gathered optimal conditions for AS-PCR. SNP genotyping of rs203878 
on ZNF165 was performed by gene sequencing. Briefly, genomic DNA (gDNA) 
was extracted from peripheral blood or stored. gDNA and amplicons containing 
the selected loci were PCR-amplified using specific primers. Amplicons were 
then electrophoresed and extracted from the gel whit the QIAquick Gel 
Extraction Kit (Quiagen). Sequencing reaction was prepared with the Big Dye 
Terminator v1.1 Cycle Sequencing kit (Applied Biosystems) and loaded in an 
ABI prism 310 Genetic Analyzer Sequencer (Applied Biosystems). 
 
HLA-A and -B genotyping 
Seventy-three subjects had been previously genotyped for HLA-A and B 
loci [12, 15, 17-18] and this information was available in their clinical records. In 
the context of the present study, HLA-A and –B genotyping was performed in 70 
additional DNA samples from the subjects described above. For this purpose, 
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DNA was amplified by polymerase chain reaction-sequence specific primers 
(PCR-SSP) for HLA class I alleles, loci A and B, based on standard well 
described methods [19]. 
 
Clinical characterization of subjects 
Phenotypic data from the subjects included in study were available from 
their clinical records at Santo António Hospital. Clinical information from these 
patients was partially described in detail elsewhere [11, 20]. For the purpose of 
characterization of patients in terms of clinical expression, they were divided in 
two groups according to the presence or absence of HH related clinical 
manifestations. These included the presence of one or more of the following 
manifestations: liver cirrhosis /fibrosis, diabetes, arthropathy, hypopituitarism, 
skin pigmentation or cardiac abnormalities. As a measure of the severity of iron 
overload we used the estimation of Total Body Iron Stores (TBIS) determined 
by quantitative phlebotomies [21]. The patients’ immunophenotype was defined 
by the total number of peripheral blood CD8+ T lymphocytes determined by 
FACS analysis as described in detail elsewhere [12]. For the purpose of 
analysis, a number of CD8+ T lymphocytes ≤0,41x106/mL is considered a “low” 
CD8+ profile, contrasting with the “high” profile when the CD8+ T lymphocyte 
numbers are above that limit. This cut-off value was defined based on the 
median value of the parameter previously established in a control population 
from north Portugal [12]. For the purpose of analysis of the CD8+ lymphocyte 
profile, some patients were excluded based on the following criteria: presence 
of lymphocytosis related with the age of the subjects (1 subject aged below 18 
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years), positive viral markers for hepatitis B virus (HBV) (n=1) and associated 
immunological disorders (n=1). 
 
Extended haplotype definition 
For the purpose of this study, extended haplotypes were defined by 
segregation analysis, by comparing the genotype information of the individuals 
homozygous for C282Y mutation with their informative family members. 
Extended haplotypes were defined with the genotype information of the 
following genetic markers: PGBD1, ZNF193 and ZNF165 and HLA-A and B 
locus. In subjects where no familiar information was available, the extended 
haplotypes were inferred using the program PHASE 
(http://www.stat.washington.edu/stephens/software.html), as described 
previously [13]. In few cases (n=10), information was missing for some 
particular alleles (on SNP markers – PGBD1, ZNF193 or ZNF165). In those 
cases, missing alleles were inferred using PHASE. 
 
Statistic analysis 
The comparison between the frequencies of AAT and GGG restricted 
SNP haplotypes between two independent patient samples was done using the 
Chi-square Test for a statistical significance value of P < 0.05. Comparisons 
between HLA allele and haplotype frequencies in different groups were done by 
Fisher Exact Test. The statistical significance of the tests was considered for a 
P value < 0.05 with further Bonferroni’s correction for multiple comparisons. 
This was done by multiplying the Fisher test P values by the number of allelic or 
haplotype comparisons. To analyze the relative strength in HLA allele or 
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haplotype associations, the etiological fraction delta (δ) was calculated as 
described according to the formula d= (FAD-FAP)/(1-FAP), where FAD is the 
allele frequency in the diseased population and FAP the allele frequency in the 
control population [22-23]. Linkage disequilibrium between the alleles was 
estimated by the standard D value, where D is the difference between the 
observed and expected frequencies of the two alleles in the same chromosome. 
The significance of the association was tested using the Fisher test and the 
statistical significance was considered for a P value < 0.05. Data were analyzed 
by Statgraphics software (Statgraphics Graphics System, version 7.0). 
 
 
To better understand the involvement of the MHC-class I markers on the 
setting of CD8+ T lymphocyte numbers, two different models were tested, 
where rules were generated for the prediction of the CD8+ T lymphocyte profile 
(“low” or “high” profile) in individual HH patients: 1) the first model assumes that 
the CD8+ T lymphocyte profile is predicted with information on HLA haplotypes, 
independently of the other SNP markers in the extended haplotypes; 2) and a 
second model where information on the restricted SNP markers is also 
included. The rules generated for each model were applied to the HH 
population under study and the predictive power (or sensitivity) as well as the 
specificity of each model were estimated. Sensitivity was determined by the 
formula: TP/(TP+FP) where TP means the number of true positive results and 
FP the number of false positive results. Specificity was determined by the 
formula: TN/(TN+FN) where TN means the number of true negative results and 
FN the number of false negative results. 
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Results 
1. AAT and GGG restricted SNP haplotype frequencies in a representative 
sample of Portuguese HH patients 
Previous studies performed by our group, using a population of 56 HH 
patients, have suggested that a highly conserved 500 Kb ancestral haplotype 
defined by the SNP markers PGBD1-A, ZNF193-A, ZNF165-T (AAT haplotype) 
marks the inheritance of “low” CD8+ T-lymphocyte numbers and predicts the 
development of a severe clinical expression of HH (in terms of iron overload 
and clinical manifestations). On the other hand, haplotype defined by the SNP 
markers PGBD1-G, ZNF193-G, ZNF165-G (GGG haplotype) marks the 
inheritance of “high” CD8+ T-lymphocyte numbers and predicts the 
development of a less severe clinical expression of HH [14]. 
In order to confirm the previous results in a larger and more 
representative population of Portuguese HH patients, the restricted SNP 
haplotypes were analyzed in the present SAH study population (n=71) and in an 
additional independent HH population designated here as CGPP population 
(see Subjects & Methods). The results are summarized in Table 1. In the SAH 
population we observed an haplotype frequency of 89.4% (n=127/142) for the 
AAT haplotype, 6.3% (n=9/142) for the GGG haplotype and 4.2% (n=6/142) for 
other haplotypes.  A similar distribution was observed in the independent CGPP 
population where haplotype frequencies of 94.3% (n=232/246) for the AAT 
haplotype, 4.9% (n=12/246) for the GGG haplotype and 0.8% (n=2/246) for 
other haplotypes were observed. A comparison between the frequencies 
observed in the two populations did not show any statistical difference. 
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A summary of the clinical phenotype of HH patients in terms of the 
presence or absence of symptoms, the total body iron stores (TBIS) at 
diagnosis, and the average number of CD8+ T lymphocytes, is also shown in 
Table 1,  in relation to the restricted SNP haplotypes.  The results show that 
53.5% of the patients with the AAT haplotype (n=31/58) were symptomatic 
patients, had on average 8.5 ± 4.7g of TBIS at diagnosis, and the average 
CD8+ T-lymphocyte count was 0.37 ± 0.2 x 106/mL.  In contrast,  only 12.5% 
(n=1/8) of the patients with the GGG haplotype were symptomatic, their 
average  TBIS at diagnosis was 3.7 ± 3.3g and the average number of  CD8+ T-
lymphocytes was 0.58 ± 0.2 x 106/mL. These results confirm the high frequency 
of AAT relative to GGG in the Portuguese HH population and confirm the 
previous observations by Cruz and co-workers [14] of the association among 
those restricted haplotypes, CD8+ lymphocyte numbers and the clinical 
expression of the disease, suggesting that they could constitute important 
prognosis markers.  In spite of its strong association, the restricted SNP 
haplotypes AAT or GGG do not explain, however, all the variability in CD8+ T 
lymphocyte numbers. In fact, an important proportion of AAT homozygous 
patients (33.3%) have high CD8+ counts, showing that other markers in the 
region are still necessary to clarify the contribution of the MHC region on the 
setting of CD8+ T lymphocyte numbers. Given the known extreme linkage 
disequilibrium in this region [3], a combined analysis with more distant markers, 
such as HLA alleles and haplotypes is warranted.   
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2. HLA allele and haplotype frequencies in C282Y carrying chromosomes 
The frequencies of HLA-A and HLA-B alleles were estimated in the group 
of unrelated C282Y homozygous subjects from the SAH study population and 
compared with a control population representative of the Portuguese normal 
population from the same geographical region (see table 2). As expected [18, 
24], after performing Bonferroni’s correction for multiple comparisons, the HLA 
alleles A*03 and B*07 were the most commonly found in C282Y homozygous 
subjects highly significantly different from controls (0.408 for A*03 and 0.238 for 
B*07 vs 0.110 and 0.060 respectively in controls; all P < 0.0001).  As also 
expected [18, 24] the strength of this association, as shown by the etiological 
fraction delta, is stronger for the HLA A*03 (δ =0.335) than the B*07 (δ =0.189). 
The HLA allele B*60 was also more common in the population of C282Y 
homozygous subjects as compared with the control population (0.014 vs 0.001; 
P < 0.0001), but the strength of this association, as shown by the etiological 
fraction delta, is very weak (δ=0.014) in comparison to those observed for the 
HLA alleles A*03 and B*07. To eliminate the eventual artificially lowered 
frequencies of other alleles that were due to the extra space occupied by HLA 
alleles A*03 and B*07, a prevalence’s correction was done in our population 
according to the method described by Simon et al. (1987) [24]. Accordingly, the 
frequency of other HLA alleles was calculated by subtracting from the 
denominator the number of HLA-A*03 or –B*07 alleles, respectively, but no 
more significant associations were observed and therefore these data are not 
shown. 
Segregation analysis by family studies, associated with haplotype 
inference by the program PHASE (see Methods), was done in order to define 
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the extended haplotypes associated with the HFE C282Y mutation in 
Portuguese HH patients. From a total of 76 C282Y homozygous individuals (the 
71 unrelated patients from the SAH study population plus 5 haploidentical 
siblings in whom only the new haplotype was retained), a total of 147 extended 
haplotypes were defined. The results are summarized in Table 3 where the 
frequencies of the extended haplotypes are compared with the expected 
haplotype frequencies in the normal population (these expected values were 
estimated with information on HLA haplotypes only). The A3B7-AAT extended 
haplotype was the most common with a frequency of 0.177 (P < 0.0001 for the 
expected normal frequency). Other extended haplotypes, namely A2B7-AAT, 
A3B14-AAT, A3B27-AAT, A3B40-AAT, A32B40-AAT, A2B51-AAT and A3B51-
AAT, were also more common in C282Y homozygous subjects as compared 
with the control population. However, the strength of association in these 
haplotypes, as shown by the etiological fractions delta, were very weak (δ<0.06) 
in comparison to the much stronger association of the A3B7-AAT extended 
haplotype (δ=0.166). In addition, the haplotype A3B7-AAT was the only one 
where the HLA alleles were in linkage disequilibrium (P = 0.0223). Like in the 
analysis of HLA alleles, a prevalence correction was performed to eliminate the 
eventual extra space occupied by the HLA haplotype A3B7 and no changes in 
results were observed (data not shown). 
 
3. Relative impact of the HLA haplotype or the full extended haplotype on 
the setting of CD8+ T lymphocyte numbers 
In order to test the relative impact of the HLA haplotypes or the full 
extended haplotype (including the information on restricted AAT or GGG 
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haplotypes) on the CD8+ T lymphocyte profile, we tested two different models 
where different rules were generated for the prediction of the CD8+ lymphocyte 
profile in individual patients. The first model was designed to test the hypothesis 
that the combination of particular HLA specificities alone can predict the CD8+ 
T lymphocyte profile (model A). The second model was designed to test the 
hypothesis that the CD8+ T lymphocyte profile can be better explained by the 
inclusion of genetic information of the SNP markers on an extended haplotype 
(model B).  
 
3.1. Predicting the CD8+ T lymphocyte profile based on HLA haplotypes 
(Model A) 
This model was tested assuming that the inheritance of CD8+ T 
lymphocyte numbers is mainly dependent on the HLA haplotypes alone. Based 
on the previous evidence by Vieira and co-workers [13] that alleles determining 
a high CD8+ T lymphocyte profile are dominant over the alleles determining a 
low profile, it was assumed that the HLA haplotypes observed in individuals with 
an unequivocal low CD8+ profile (arbitrarily established below 0,35 x106/mL) 
should always predict a low CD8+ profile. Using a sub-population of 37 subjects 
with unequivoval low CD8+ profiles, 29 HLA haplotypes were assigned: A3B7, 
A3B8, A3B14, A3B18, A3B27, A3B35, A3B40, A3B44, A3B51, A2B7, A2B14, 
A2B15, A2B27, A2B44, A2B51, A1B8, A1B15, A1B35, A1B44, A1B57, A11B8, 
A24B27, A24B35, A26B35, A26B40, A29B58, A32B18, A32B40, A33B14. As 
expected from the previous results by Cruz et al. (2006) [15] the large majority 
of these haplotypes (82.4%) carry the most common HLA alleles A*03, A*02 or 
A*01. We next generated a rule where all individuals who carry two of the 
  58 
assigned haplotypes are expected to have a low CD8+ profile, while individuals 
who carry only one or none of these haplotypes are expected to have a high 
profile. We tested the model in a population of 84 C282Y homozygous subjects 
(65 probands and 19 family members, all having information on CD8+ T 
lymphocyte numbers) and the results show that this predictive model has a 
sensitivity of 95.8% (46/48 correctly predicted positive outcomes) but a 
specificity of only 66.7% (24/36 correctly predicted negative outcomes), in 
accordance with data previously published by Vieira et al. (2007) in a normal 
population where they could better  predict correctly low numbers of CD8+ T 
lymphocytes than high numbers [13]. The finding of a low specificity of the 
predictive model may signify either those other independent factors are 
influencing the high CD8+ T cell numbers or that other markers in the region are 
better predictors, an hypothesis further explored with the next model. 
 
3.2. Predicting the CD8+ T lymphocyte profile based on full extended 
haplotype information (Model B) 
This model was designed to test if the inclusion of genetic information on 
the SNP markers on PGBD1-A, ZNF193-A, ZNF165-T on the extended 
haplotype could increase the sensitivity and/or specificity of the previous model. 
For that purpose, we used the previous rule on HLA haplotype information 
predicting a low CD8+ T lymphocyte profile and added a new rule where the 
presence of the restricted SNP haplotype GGG predicts a high CD8+ T 
lymphocyte profile. By applying this model to the same population of 84 C282Y 
homozygous subjects, the test sensitivity decreased from 95.8 to 91.7% and the 
test specificity increase from 66.7 to 69.4%. In spite of the slight increase in the 
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specificity of this model, it turned to be instead less sensitive, therefore it still 
does not explain the association, implying that a putative genetic trait 
determining the numbers of CD8+ T lymphocytes is not any of the tested 
markers but could be still another unidentified associated marker or a 
combination of more than one marker in the region. Work is on progress to 
further enlarge the region of interest to look for one or more candidate gene(s) 
by a deep sequencing study of the whole region including all HLA loci. 
 
4. A new working model assigning a “low” or “high CD8+ trait” in each 
C282Y carrying chromosome 
Globally, the results presented above support the hypothesis that the 
inheritance of CD8+ T lymphocyte numbers may be associated with an 
independent trait localized in the MHC-class I region in strong linkage with the 
other genetic markers tested but its precise localization is still elusive. As an 
approach to test that hypothesis, a new working model was designed where, 
based on the extended haplotype information plus the associated CD8+ 
lymphocyte profile, a putative genetic trait of “low” or “high” CD8+ T 
lymphocytes was assigned to each C282Y carrying chromosome from the study 
population. Based on the known distribution of CD8+ T lymphocyte numbers in 
the population [8, 11, 25] we considered that the putative genetic trait 
associated with CD8+ T lymphocyte numbers is transmitted in a co-dominant 
mode. For the purpose of constructing the model, all extended haplotypes 
observed in subjects with unequivocal low CD8+ T lymphocyte numbers 
(arbitrarily established below 0.35 x106/mL such as in model A) were assumed 
to be linked to a “low CD8+ trait”. On the contrary, all extended haplotypes 
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observed in subjects with unequivocal high CD8+ T lymphocyte numbers 
(arbitrarily established above 0.45 x106/mL) were assumed to be linked to a 
“high CD8+ trait”. Finally, in all subjects whose CD8+ lymphocyte numbers were 
between 0.35 and 0.45 x106/mL, we considered that they inherited a 
combination of a “low” with a “high CD8+ trait”. In each of these individuals their 
extended haplotypes were compared with those previously assigned as “low” or 
“high” and classified accordingly. If they carried an extended haplotype that had 
not been assigned before, it was assigned as “low CD8+ trait” if he carried a 
“high CD8+ trait” in trans, and was assigned as “high CD8+ trait” if he carried a 
“low CD8+ trait” in trans. With this strategy, we were able to classify all the 147 
extended haplotypes with 100% fitness.   
Having constructed the model with all patients’ chromosomes classified 
as carrying a “low” or “high CD8+ trait”, we next tested the hypothesis that they 
could have had an independent recombination history. This was done by 
comparing the distribution of HLA alleles and haplotypes between the two 
groups of chromosomes (see next chapters). 
 
5. HLA allele and haplotype frequencies in C282Y carrying chromosomes 
according to the CD8+ trait 
In order to explore the recombination history of C282Y carrying 
chromosomes associated with a “low” or “high CD8+ trait”, the frequencies of 
HLA-A and HLA-B alleles and HLA haplotypes were estimated in the 147 
extended haplotypes from the C282Y homozygous patients studied, and 
compared, first with the expected frequencies obtained from the control 
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population and then compared between the two groups of chromosomes with a 
“low” or “high CD8+ trait” (results summarized in Tables 4-6).  
 
5.1 HLA allele frequencies in C282Y chromosomes carrying a “low CD8+ 
trait” 
As shown in Table 4, after applying a Bonferroni’s correction for multiple 
comparisons, it was observed that, in chromosomes carrying a “low CD8+ trait”, 
the  HLA alleles A*02, A*03, A*24, A*29, B*07 and B*44 were significantly more 
common than in the control population (respectively 0.203, 0.456, 0.025, 0.013, 
0.291 and 0.076 in patients’ chromosomes vs 0.263, 0.110, 0.104, 0.053, 0.060 
and 0.152 in controls; all P < 0.005). However, the strength of the association, 
as evaluated by the etiological fraction delta, was remarkably stronger for the 
HLA alleles A*03 and B*07, the association of A*03 being stronger than B*07 
(δ-value=0.388 and 0.246, respectively). To eliminate the artificially lowered 
frequencies of other alleles that were due to the extra space occupied by HLA 
alleles A*03 and B*07, a prevalence’s correction was done in our population 
according to the method described by Simon et al. (1987) [24]. Thus, the 
frequency of other HLA alleles was calculated by subtracting from the 
denominator the number of HLA-A3 or -B7 alleles, respectively. This corrected 
prevalence then allowed a more meaningful comparison between the 
frequencies of the HLA alleles in patients’ chromosomes and in controls (see 
Table 4). With this correction performed, it is apparent that HLA alleles A*01 
and B*40 are also significantly more common in chromosomes carrying a “low 
CD8+ trait” as compared with controls (0.279 and 0.161 vs 0.111 and 0.033 
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respectively; all P < 0.005) and that the association with the HLA allele A*01 is 
a strong one, as evidenced by the etiological fraction delta (δ =0.189). 
 
5.2 HLA allele frequencies in C282Y chromosomes carrying a “high CD8+ 
trait” 
In large contrast with the results observed in chromosomes carrying a 
“low CD8+ trait”, after performing Bonferroni’s correction for multiple 
comparisons in the “high CD8+ trait” group of chromosomes, we observed that 
only the HLA allele A*03 was significantly more common than in the control 
population (0.358 vs 0.110 respectively; P < 0.0001) with a strong association 
as evaluated by the etiological fraction delta (δ =0.279). Even after applying a 
prevalence’s correction for the high frequency of HLA allele A*03, no other HLA 
allele appeared in significantly higher frequencies (data not shown). Curiously, 
the most common HLA-B allele in these chromosomes was not the B*07 (as 
expected by its higher frequency in HH in general) but the B*44 that is the most 
common allele in the normal population.  
 
5.3 HLA haplotype frequencies in C282Y chromosomes carrying a “low 
CD8+ trait” 
In terms of HLA haplotypes associated with a “low CD8+ trait”, the A3B7 
is the most common with a frequency of 0.203 (P < 0.0001). Other haplotypes 
were also significantly more common (see Table 5) but only the A3B7 haplotype 
had a strong association as revealed by the etiological fraction delta (δ =0.192). 
In these chromosomes, we confirmed the linkage disequilibrium between the 
HLA-A*03 and –B*07 alleles (P = 0.0368). A prevalence’s correction was also 
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performed to compensate for the very high frequency of the haplotype A3B7, 
and after that, the HLA haplotypes A2B7 and A3B40 were also shown to be 
significantly more common in chromosomes carrying the “low CD8+ trait” as 
compared with controls (0.111 and 0.079 vs 0.0001 and 0.0001 respectively; all 
P < 0.0001), although only the A2B7 haplotype had a strong association as 
shown by the etiological fraction delta (δ-value=0.111).  
 
5.4 HLA haplotype frequencies in C282Y chromosomes carrying a “high 
CD8+ trait” 
Again, the results obtained for chromosomes carrying a “high CD8+ trait”, 
in terms of HLA haplotypes, largely contrast with those obtained for 
chromosomes carrying a “low CD8+ trait”. Although the HLA-A3B7 haplotype is 
also the most common, with a frequency of 0.151 (P < 0.0001), the strength of 
association is clearly lower (δ-value=0.140). Moreover, contrary to what is 
generally observed in C282Y carrying chromosomes, the linkage disequilibrium 
between HLA-A*03 and –B*07 is not confirmed (P = 0.5552). After applying the 
prevalence’s correction no other significant differences were observed.   
 
5.5 Comparing HLA allele and haplotype distributions in C282Y 
chromosomes carrying a “low” or “high CD8+ trait” 
We next compared HLA alleles and haplotype distributions in 
chromosomes grouped according to the “low” or “high” CD8+ trait and no 
significant differences were observed for either HLA-A or -B alleles between the 
two groups. The most striking result, however, was the evident greater allelic 
variability in the group with a “high CD8+ trait” in comparison to the group with 
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“low CD8+ trait” both for the HLA-A alleles (respectively a total of 12 different 
alleles in 53 chromosomes vs a total of 9 alleles in 79 chromosomes) and the 
HLA-B alleles (respectively a total of 17 alleles in 53 chromosomes vs a total of 
13 alleles in 79 chromosomes). Haplotypic variability was also greater in the 
group with a “high CD8+ trait” in comparison to the group with “low CD8+ trait” 
(respectively a total of 36 different haplotypes in 53 chromosomes vs a total of 
30 haplotypes in 79 chromosomes). Figures 1-3 are illustrative of these results. 
  65 
Discussion 
The present study was designed to explore the question of the 
association of the MHC-class I region with the genetic regulation of CD8+ T 
lymphocyte numbers in humans. 
Low numbers of CD8+ T cells, both in peripheral blood and in the liver, 
are known to be negatively correlated with liver iron stores in HH [2, 11, 25]. 
Therefore, this immunophenotype profile is proposed to be a good clinical 
marker of the severity of iron overload in HH patients [11, 14]. 
It is known that CD8+ T lymphocyte numbers are genetically regulated, 
and partially influenced by genes localized at the MHC region. This was first 
demonstrated in humans in studies performed in HH patients [12]. Those 
studies also support the hypothesis that a putative MHC-linked gene(s) 
controlling CD8+ T cell numbers could be the same gene contributing to the 
clinical heterogeneity observed in HH [12-13, 15]. 
Based on the evidence described by Cruz et al (2008) [14], the highly 
conserved 500 Kb haplotype (around the microsatellite D6S105) defined by the 
SNP markers PGBD1, ZNF193, ZNF165 seemed to be a very promising region 
where the putative gene controlling CD8+ T cell numbers could be localized.  In 
the present work, we confirmed a high frequency of the AAT relative to the 
GGG haplotype and its general association with low or high CD8+ T 
lymphocytes respectively. It would seem attractive to further narrow the region 
within this restricted haplotype trying to find a putative gene(s) involved in CD8+ 
T lymphocyte regulation. However, taking as an example the strategy used by 
Feder and co-workers when they discovered the HFE gene associated with HH 
[3] we decided as the next step to enlarge instead of trying to narrow the region 
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of interest, assuming the extreme linkage disequilibrium in the region [26]. 
Based on this assumption, we evaluated the MHC region from the HFE gene to 
the HLA-B, a region constituted by about 4Mb (gene markers used are, from 
centromeric position to telomeric position, HLA-B, HLA-A, PGBD1, ZNF193, 
ZNF165 and the HFE mutation) and correlated that information with the CD8+ T 
lymphocyte profile. This allowed us to construct a model of conserved extended 
haplotypes marking the inheritance of the putative genetic trait setting a “low” or 
a “high” CD8+ T lymphocyte profile. 
With this approach, we observed a strong association among the HLA 
haplotype A3B7, the restricted haplotype AAT and the C282Y mutation, with a 
strong linkage disequilibrium between the HLA-A*03 and -B*07 alleles as 
described before [18, 24-25], confirming the remarkable conservation of an 
ancestral extended haplotype carrying the C282Y mutation [14]. This extended 
haplotype was the most commonly found in HH patients with both a low and a 
high CD8+ lymphocyte profile. But curiously, the pattern of linkage 
disequilibrium was different in chromosomes carrying or not a genetic trait 
associated with low CD8+ T lymphocytes. This was observed by an analysis of 
the HLA allele and haplotype distribution in two groups of chromosomes, i.e.,  
those carrying a “low” and those carrying a “high CD8+ trait”, here defined by a 
complex segregation analysis of extended haplotypes (see results, section 4).  
Although the HLA-A3B7 haplotype was the most commonly found in both 
groups, the linkage disequilibrium between the HLA-A*03 and -B*07 alleles was 
only observed in chromosomes carrying the “low CD8+ trait” suggesting that the 
two groups of chromosomes may have a distinct recombination history.  In 
accordance to that is the fact that HLA diversity is much higher in chromosomes 
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carrying the “high CD8+ trait”, in spite of the lower number of chromosomes 
observed. In contrast, the “low CD8+ trait” chromosomes show a higher 
conservation not only of the most common HLA-A3B7 haplotype, but also other 
haplotypes (although with much less strong association) suggesting some kind 
of positive selection. 
The fact that the only HLA allele significantly associated in all 
chromosomes (carrying either the “low” or the “high CD8+ trait”) is the HLA-
A*03, in association with the extended haplotype A3B7-AAT, points to the 
conservation of the region between HFE mutation and HLA-A independently of 
CD8+ T cell numbers. This suggests that the putative CD8+ T lymphocyte trait 
may be localized centromeric to the HLA-A. Although in this study no direct 
association was found with the HLA-B locus, this does not rule out the 
hypothesis that the putative gene may be in this region. Recently, Ferreira et al 
(2010) demonstrated the existence of an imputed SNP (rs2524054) located in 
the MHC class I gene cluster (in HLA-C region, next to HLA-B) that influenced 
the CD4:CD8 ratio and CD8 levels [27]. The authors also show that the A allele 
of rs2524054 (class I) was associated with decreased CD8 levels. We still 
cannot rule out, however, the hypothesis that the candidate gene involved in the 
setting of CD8+ T-lymphocyte numbers may be in a more centromeric region in 
relation to HLA-B. Supporting that idea is the evidence of a higher allelic and 
haplotypic variability in the “high” comparatively to the “low CD8+ trait” carrying 
chromosomes. The best way to clarify the questions raised is to perform a deep 
sequencing of the whole region including all HLA loci in informative patients 
regarding their CD8+ T lymphocyte profiles. 
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The novel finding that the same ancestral haplotype A3B7-AAT is 
common in both low and high CD8+ T lymphocyte numbers (although much 
more commonly with low) raises a new question about the evolutionary history 
of the HH haplotypes in the HH population. It is generally well accepted that the 
hemochromatosis mutation was a recent event which occurred on a founder 
chromosome carrying the HLA-A3B7 haplotype [24]. Later studies have shown 
that the number of copies of the ancestral haplotype was associated with the 
clinical expression, with a more severe phenotype observed in patients carrying 
two copies of the ancestral haplotype as compared with those with one or 
without any copy [28-29]. In 2006 Cruz et al. hypothesised that the most 
ancestral C282Y carrying HLA-A3-B7 haplotype also carried the genetic trait 
determining low CD8+ T lymphocytes and that the more diverse haplotypes 
associated with high CD8+ T lymphocytes should be more recent in the 
evolutionary history of the HH haplotypes, as expected by recombinational 
events along generations [15]. The present results could support a new 
alternative hypothesis where the most ancestral HFE mutation could have 
originally evolved in a high diversity of HLA haplotypes in association with a 
high CD8+ T lymphocyte profile, and more recently a selective sweep occurred 
increasing significantly the frequency of the particular haplotype A3B7-AAT 
associated with low lymphocyte numbers, from which other haplotypes 
associated with low CD8+s could have been further derived by recombination.  
This could eventually explain the finding of a general low penetrance of the 
C282Y mutation (putatively associated with high lymphocytes and mild iron 
overload) and the remarkable high frequency of the HLA HLA-A3B7 haplotype 
in patients expressing the disease. It is well known that, despite being a 
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mutation of high prevalence in Caucasians (1 in 200people) [5] the number of 
symptomatic patients is not as high as expected.  
 
Conclusions 
An important message deriving from this study is that in all studies 
addressing the question of the penetrance of Hereditary Hemochromatosis, the 
evaluation of CD8+ T lymphocyte numbers should be included as an important 
marker. The eventual finding of a putative gene involved in the setting of CD8+ 
T lymphocyte numbers could be of a great value as a new genetic marker not 
only for the prognosis and penetrance of Hereditary Hemochromatosis, but also 
in all clinical situations where CD8+ T lymphocytes are important players. The 
present study points, for the first time, to a possible localization of that putative 
gene centromeric to the HLA-A locus. 
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Figures 
Figure 1 
Short Title: HLA-A distribution according to the CD8+ T lymphocytes number 
trait. 
  
 
Figure 2 
Short Title: HLA-B distribution according to the CD8+ T lymphocytes number 
trait. 
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Figure 3 
Short Title: HLA haplotype distribution according to the CD8+ T lymphocytes 
number trait. 
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Tables and Captions 
Table 1 – Haplotype frequencies of SNP markers in unrelated C282Y 
homozygous subjects. 
 
* For the purpose of haplotype definition in 106 subjects from the independent 
CGPP population, where complete information on SNP genotyping was not 
available, the AAT haplotype was assigned based on the presence of at least 
the A-allele on PGBD1. The expected error in these cases is not greater than 
1.41% (2/142) as estimated by the general frequency of PGBD1-A individuals 
who are not AAT. 
 
 
 
Independent CGPP 
population 
SAH study population 
(n=71) 
 
Haplotype 
frequency 
(n=123) 
Haplotype 
frequency 
Total CD8+ T 
cells (x10
6
/ml) 
TBIS (g) 
Symptomatic 
patients 
AAT* 
94.3% 
(232/246) 
89.4% 
(127/142) 
0.37 ± 0.20 
(0.08 – 0.77) 
(n=54) 
8.5 ± 4.66 
(1.1 – 17.4) 
(n=40) 
53.5% 
(31/58) 
GGG 
4.9% 
(12/246) 
6.3% 
(9/142) 
0.58 ± 0.23 
(0.28 – 1.04) 
(n=8) 
3.7 ± 3.30 
(1.4 – 9.9) 
(n=6) 
12.5% 
(1/8) 
Others 
0.8% 
(2/246) 
4.2% 
(6/142) 
- 
14.3 ± 4.90 
(8.7 – 18.1) 
(n=3) 
100% 
(3/3) 
  81 
Table 2 – HLA allele frequencies in unrelated C282Y homozygous subjects. 
H
L
A
-A
 
HLA N FreqSP FreqCP** Fisher δ 
1 18 0.122 0.111 n.s. - 
2 26 0.177 0.263 n.s. - 
3 60 0.408 0.110 0.0001 0.335 
11 6 0.041 0.069 n.s. - 
23 5 0.034 0.045 n.s. - 
24 6 0.041 0.104 n.s. - 
25 2 0.014 0.015 n.s. - 
26 3 0.020 0.035 n.s. - 
29 5 0.034 0.053 n.s. - 
31 2 0.014 0.025 n.s. - 
32 6 0.041 0.039 n.s. - 
33 4 0.027 0.033 n.s. - 
34 1 0.007 0.004 n.s. - 
68 3 0.020 0.047 n.s. - 
 
H
L
A
-B
 
7 35 0.238 0.060 0.0001 0.189 
8 15 0.102 0.074 n.s. - 
13 1 0.007 0.001 n.s. - 
14 6 0.041 0.068 n.s. - 
15 4 0.027 0.057 n.s. - 
18 7 0.048 0.049 n.s. - 
27 5 0.034 0.031 n.s. - 
35 16 0.109 0.118 n.s. - 
37 3 0.020 0.015 n.s. - 
38 2 0.014 0.022 n.s. - 
40 10 0.068 0.033 n.s. - 
41 1 0.007 0.009 n.s. - 
42 1 0.007 0.001 n.s. - 
44 18 0.122 0.152 n.s. - 
47 1 0.007 0.002 n.s. - 
49 1 0.007 0.001 n.s. - 
51 11 0.075 0.109 n.s. - 
55 1 0.007 0.014 n.s. - 
56 1 0.007 0.004 n.s. - 
57 5 0.034 0.030 n.s. - 
58 1 0.007 0.018 n.s. - 
60 2 0.014 0.001 0.0001 0.014 
67 1 0,007 0.001 n.s. - 
 
** Control population (CP) is composed by a total of 7937 individuals (15874 
HLA-A and -B alleles) from the region of Porto, Portugal. Results are published 
in: “New Allele Frequency Database: http://www.allelefrequencies.net. 
Middleton D, Menchaca L, Rood H, Komerofsky R. Tissue Antigens 2003, 61, 
403-407”. 
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Table 3 – HLA haplotype frequencies in unrelated C282Y homozygous 
subjects. 
HLA SNP N FreqSP FreqPC*** Fisher δ 
A2B7 AAT 8 0.054 0.0001 0.0001 0.054 
A3B7 AAT 26 0.177 0.0130 0.0001 0.166 
A34B7 AAT 1 0.007 0.0001 n.s. - 
A1B8 
AAT 7 0.048 
0.0340 n.s. - 
GGT 1 0.007 
A2B8 AAT 1 0.007 0.0001 n.s. - 
A3B8 
AAT 3 0.020 
0.0001 n.s. - 
AGG 1 0.007 
A11B8 AAT 2 0.014 0.0001 n.s. - 
A1B13 AAT 1 0.007 0.0001 n.s. - 
A2B14 AAT 1 0.007 0.0110 n.s. - 
A3B14 AAT 3 0.020 0.0001 0.0001 0.020 
A33B14 GGG 2 0.014 0.0130 n.s. - 
A1B15 AAT 1 0.007 0.0001 n.s. - 
A2B15 AAT 2 0.014 0.0110 n.s. - 
A3B18 AAT 1 0.007 0.0001 n.s. - 
A24B18 AAT 2 0.014 0.0001 n.s. - 
A25B18 AAT 2 0.014 0.0001 n.s. - 
A32B18 AAT 2 0.014 0.0001 n.s. - 
A2B27 AAT 1 0.007 0.0001 n.s. - 
A3B27 AAT 3 0.020 0.0001 0.0001 0.020 
A24B27 AAT 1 0.007 0.0001 n.s. - 
A1B35 AAT 2 0.014 0.0001 n.s. - 
A2B35 
AAT 1 0.007 
0.0100 n.s. - 
GGG 1 0.007 
A3B35 AAT 8 0.054 0.0120 n.s. - 
A24B35 AAT 1 0.007 0.0110 n.s. - 
A26B35 AAT 1 0.007 0.0001 n.s. - 
A31B35 AAT 2 0.014 0.0001 n.s. - 
A1B37 AAT 1 0.007 0.0001 n.s. - 
A11B37 AAT 1 0.007 0.0001 n.s. - 
A29B37 GGG 1 0.007 0.0001 n.s. - 
A68B38 AAT 2 0.014 0.0001 n.s. - 
A3B40 AAT 5 0.034 0.0001 0.0001 0.034 
A26B40 AAT 1 0.007 0.0001 n.s. - 
A32B40 AAT 3 0.020 0.0001 0.0001 0.020 
A33B40 AAT 1 0.007 0.0001 n.s. - 
A3B41 AAT 1 0.007 0.0001 n.s. - 
A29B42 AGG 1 0.007 0.0001 n.s. - 
A1B44 AAT 1 0.007 0.0001 n.s. - 
A2B44 AAT 4 0.027 0.0150 n.s. - 
A3B44 AAT 2 0.014 0.0001 n.s. - 
A11B44 GGG 1 0.007 0.0001 n.s. - 
A23B44 
AAT 1 0.007 
0.0120 n.s. - AGG 1 0.007 
GGG 3 0.020 
A24B44 AAT 1 0.007 0.0140 n.s. - 
A29B44 GAT 2 0.014 0.0190 n.s. - 
A33B44 AAT 1 0.007 0.0001 n.s. - 
A68B44 GGG 1 0.007 0.0001 n.s. - 
A3B47 AAT 1 0.007 0.0001 n.s. - 
A2B49 AAT 1 0.007 0.0001 n.s. - 
A2B51 AAT 6 0.041 0.0001 0.0001 0.041 
  83 
A3B51 AAT 4 0.027 0.0001 0.0001 0.027 
A11B51 AAT 1 0.007 0.0001 n.s. - 
A11B55 AAT 1 0.007 0.0001 n.s. - 
A26B56 AAT 1 0.007 0.0001 n.s. - 
A1B57 AAT 3 0.020 0.0130 n.s. - 
A3B57 AAT 1 0.007 0.0001 n.s. - 
A24B57 AAT 1 0.007 0.0001 n.s. - 
A29B58 AAT 1 0.007 0.0001 n.s. - 
A1B60 AAT 1 0.007 0.0001 n.s. - 
A32B60 AAT 1 0.007 0.0001 n.s. - 
A3B67 AAT 1 0.007 0.0001 n.s. - 
 
*** Control population is composed by a total of 7937 individuals (15874 HLA 
haplotypes) from the region of Porto, Portugal. Results are published in: “New 
Allele Frequency Database: http://www.allelefrequencies.net. Middleton D, 
Menchaca L, Rood H, Komerofsky R. Tissue Antigens 2003, 61, 403-407”. 
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Table 4 – HLA allele frequencies in C282Y homozygous subjects related with 
CD8+ T lymphocytes number trait. 
 High CD8+ T-lymphocytes 
number trait  
 Low CD8+ T-lymphocytes number trait 
 Uncorrected data Corrected data 
H
L
A
-A
 
HLA N FreqSP Fisher δ FreqPC** N FreqSP Fisher δ FreqSP Fisher δ 
1 4 0.075 n.s. - 0.111 12 0.152 n.s. - 0.279 0.0020 0.189 
2 7 0.132 n.s. - 0.263 16 0.203 0.0001 -0.082 0.372 n.s. - 
3 19 0.358 0.0001 0.279 0.110 36 0.456 0.0001 0.388  
11 1 0.019 n.s. - 0.069 3 0.038 n.s. - 0.070 n.s. - 
23 5 0.094 n.s. - 0.045    
24 4 0.075 n.s. - 0.104 2 0.025 0.0001 -0.088 0.047 n.s. - 
25 2 0.038 n.s. - 0.015    
26 1 0.019 n.s. - 0.035 2 0.025 n.s. - 0.047 n.s. - 
29 3 0.057 n.s. - 0.053 1 0.013 n.s. - 0.023 n.s. - 
31 2 0.038 n.s. - 0.025    
32  0.039 5 0.063 n.s. - 0.116 n.s. - 
33 2 0.038 n.s. - 0.033 2 0.025 n.s. - 0.047 n.s. - 
68 3 0.057 n.s. - 0.047    
 
H
L
A
-B
 
7 9 0.170 n.s. - 0.060 23 0.291 0.0001 0.246  
8 4 0.075 n.s. - 0.074 9 0.114 n.s. - 0.161 n.s. - 
14  0.068  0.063 n.s. - 0.089 n.s. - 
15 1 0.019 n.s. - 0.057 2 0.025 n.s. - 0.036 n.s. - 
18 4 0.075 n.s. - 0.049 3 0.038 n.s. - 0.054 n.s. - 
27  0.031  0.051 n.s. - 0.071 n.s. - 
35 9 0.170 n.s. - 0.118 7 0.089 n.s. - 0.125 n.s. - 
37 2 0.038 n.s. - 0.015    
38 2 0.038 n.s. - 0.022    
40 1 0.019 n.s. - 0.033 9 0.114 n.s. - 0.161 0.0001 0.132 
41 1 0.019 n.s. - 0.009    
42 1 0.019 n.s. - 0.001    
44 10 0.189 n.s. - 0.152 6 0.076 0.0001 -0.090 0.107 n.s. - 
47 1 0.019 n.s. - 0.002    
51 3 0.057 n.s. - 0.109 6 0.076 n.s. - 0.107 n.s. - 
55  0.014 1 0.013 n.s. - 0.018 n.s. - 
56 1 0.019 n.s. - 0.004    
57 2 0.038 n.s. - 0.030 3 0.038 n.s. - 0.054 n.s. - 
58  0.018 1 0.013 n.s. - 0.018 n.s. - 
60 1 0.019 n.s. - 0.000    
67 1 0.019 n.s. - 0.000    
 
** Control population (CP) is composed by a total of 7937 individuals (15874 
HLA-A and -B alleles) from the region of Porto, Portugal. Results are published 
in: “New Allele Frequency Database: http://www.allelefrequencies.net. 
Middleton D, Menchaca L, Rood H, Komerofsky R. Tissue Antigens 2003, 61, 
403-407”. 
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Table 5 – HLA haplotypes frequencies in C282Y homozygous subjects related 
with low CD8+ T lymphocytes number trait. 
CHROMOSOMES CARRYING THE LOW CD8+ NUMBER TRAIT 
HLA SNP Uncorrected data FreqPC** Corrected data 
N FreqSP Fisher δ FreqSP Fisher δ 
A2B7 AAT 7 0.089 0.0001 0.089 0.0001 0.111 0.0001 0.111 
A3B7 AAT 16 0.203 0.0001 0.192 0.0130  
A1B8 AAT 6 0.076 n.s. - 0.0340 0.095 n.s. - 
A3B8 AGG 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A11B8 AAT 2 0.025 0.0001 0.025 0.0001 0.032 0.0001 0.032 
A2B14 AAT 1 0.013 n.s. - 0.0110 0.016 n.s. - 
A3B14 AAT 2 0.025 0.0001 0.025 0.0001 0.032 0.0001 0.032 
A33B14 GGG 2 0.025 n.s. - 0.0130 0.032 n.s. - 
A1B15 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A2B15 AAT 1 0.013 n.s. - 0.0110 0.016 n.s. - 
A3B18 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A32B18 AAT 2 0.025 0.0001 0.025 0.0001 0.032 0.0001 0.032 
A2B27 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A3B27 AAT 2 0.025 0.0001 0.025 0.0001 0.032 0.0001 0.032 
A24B27 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A1B35 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A3B35 AAT 4 0.051 n.s. - 0.0120 0.063 n.s. - 
A24B35 AAT 1 0.013 n.s. - 0.0110 0.016 n.s. - 
A26B35 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A3B40 AAT 5 0.063 n.s. - 0.0001 0.079 0.0001 0.079 
A26B40 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A32B40 AAT 3 0.038 0.0001 0.038 0.0001 0.048 0.0001 0.048 
A1B44 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A2B44 AAT 3 0.038 n.s. - 0.0150 0.048 n.s. - 
A3B44 AAT 2 0.025 0.0001 0.025 0.0001 0.032 0.0001 0.032 
A2B51 AAT 3 0.038 0.0001 0.038 0.0001 0.048 0.0001 0.048 
A3B51 AAT 3 0.038 0.0001 0.038 0.0001 0.048 0.0001 0.048 
A11B55 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
A1B57 AAT 3 0.038 n.s. - 0.0130 0.048 n.s. - 
A29B58 AAT 1 0.013 n.s. - 0.0001 0.016 n.s. - 
 
*** Control population (CP) is composed by a total of 7937 individuals (15874 
HLA haplotypes) from the region of Porto, Portugal. Results are published in: 
“New Allele Frequency Database: http://www.allelefrequencies.net. Middleton 
D, Menchaca L, Rood H, Komerofsky R. Tissue Antigens 2003, 61, 403-407”. 
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Table 6 – HLA haplotype frequencies in C282Y homozygous subjects with high 
CD8+ T lymphocytes number trait. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** Control population (CP) is composed by a total of 7937 individuals (15874 
HLA haplotypes) from the region of Porto, Portugal. Results are published in: 
“New Allele Frequency Database: http://www.allelefrequencies.net. Middleton 
D, Menchaca L, Rood H, Komerofsky R. Tissue Antigens 2003, 61, 403-407”. 
 
 
CHROMOSOMES CARRYING THE HIGH CD8+ NUMBER TRAIT 
HLA SNP N FreqSP FreqPC*** Fisher δ 
A2B7 AAT 1 0.019 0.0001 n.s. - 
A3B7 AAT 8 0.151 0.0130 0.0001 0.140 
A1B8 AAT 1 0.019 0.0340 n.s. - 
A2B8 AAT 1 0.019 0.0001 n.s. - 
A3B8 AAT 2 0.038 0.0001 0.0001 0.038 
A2B15 AAT 1 0.019 0.0110 n.s. - 
A24B18 AAT 2 0.038 0.0001 0.0001 0.038 
A25B18 AAT 2 0.038 0.0001 0.0001 0.038 
A1B35 AAT 1 0.019 0.0001 n.s. - 
A2B35 AAT 1 0.019 
0.0100 n.s. - 
A2B35 GGG 1 0.019 
A3B35 AAT 4 0.075 0.0120 n.s. - 
A31B35 AAT 2 0.038 0.0001 0.0001 0.038 
A1B37 AAT 1 0.019 0.0001 n.s. - 
A29B37 GGG 1 0.019 0.0001 n.s. - 
A68B38 AAT 2 0.038 0.0001 0.0001 0.038 
A33B40 AAT 1 0.019 0.0001 n.s. - 
A3B41 AAT 1 0.019 0.0001 n.s. - 
A29B42 AGG 1 0.019 0.0001 n.s. - 
A2B44 AAT 1 0.019 0.0150 n.s. - 
A23B44 AAT 1 0.019 
0.0120 n.s. - A23B44 AGG 1 0.019 
A23B44 GGG 3 0.057 
A24B44 AAT 1 0.019 0.0140 n.s. - 
A29B44 GAT 1 0.019 0.0190 n.s. - 
A33B44 AAT 1 0.019 0.0001 n.s. - 
A68B44 GGG 1 0.019 0.0001 n.s. - 
A3B47 AAT 1 0.019 0.0001 n.s. - 
A2B51 AAT 1 0.019 0.0001 n.s. - 
A3B51 AAT 1 0.019 0.0001 n.s. - 
A11B51 AAT 1 0.019 0.0001 n.s. - 
A26B56 AAT 1 0.019 0.0001 n.s. - 
A3B57 AAT 1 0.019 0.0001 n.s. - 
A24B57 AAT 1 0.019 0.0001 n.s. - 
A1B60 AAT 1 0.019 0.0001 n.s. - 
A3B67 AAT 1 0.019 0.0001 n.s. - 
